ArticleBone & joint open2025
Limb-sparing surgery combined with local inactivation by ablation improves local control in soft-tissue sarcomas : a comparative study with long-term follow-up.
Article in Bone & joint open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IL-18 derived from microwave-ablated osteosarcoma facilitates antitumor response.Journal for immunotherapy of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Soft-tissue sarcoma (STS) is a rare, aggressive malignancy with a high risk of recurrence when invading surrounding structures, and the optimal treatment strategy for safe surgical margins is still unclear. This study aimed to evaluate the safety and efficacy of combined local inactivation by ablation in STS during limb-sparing surgery in high-risk STS patients. Methods: A retrospective cohort study was conducted on 44 patients between 1 January 2018 and 31 December 2022, at a tertiary medical centre. The patients were divided into two groups based on whether combined microwave in situ ablation (MWA) was performed during surgery (MWA group, n = 24 vs Control group, n = 20). The two groups were compared for postoperative complications, local disease-free survival (DFS), overall survival (OS), and progression-free survival (PFS). Results: At the last follow-up, 12 patients in the Control group and eight patients in the MWA group experienced local recurrence. The MWA group showed longer local DFS than the Control group (48.02 (SD 4.70), 95% CI 38.81 to 57.23 vs 33.91 (SD 6.54), 95% CI 21.10 to 46.71; p = 0.047). Postoperative complications showed no significant difference (MWA: 33.3% vs Control 25%, p = 0.143). No significant differences were observed in the median OS (MWA: 53.10 (SD 6.91), 95% CI 39.55 to 66.75) compared with Control (58.30 (SD 4.66), 95% CI 49.16 to 67.44; p = 0.512) and median PFS (MWA: 16.67 (SD 3.75), 95% CI 9.32 to 23.97) compared with Control (12.62 (SD 5.88), 95% CI 1.10 to 24.09; p = 0.691) between the two groups. Conclusion: The combined in situ ablation inactivation in high-risk STS during limb-sparing surgery can improve local tumour control and prolong local disease-free survival.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.